Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Rx Law Would Fundamentally Change, Not End, Drug Pricing Debate

Executive Summary

A House proposal to fund federal cost-effectiveness trials of pharmaceuticals may be a sign of things to come if the Medicare prescription drug legislation is enacted this year
Advertisement

Related Content

Follow-On Biologics Law “Inevitable,” Sen. Hatch Says; BIO Must “Engage”
Follow-On Biologics Law “Inevitable,” Sen. Hatch Says; BIO Must “Engage”
Senate Medicare Bill Directs GAO To Study International Price Controls
Senate Medicare Bill Directs GAO To Study International Price Controls
Medicare Rx Debate Moves Forward; Kennedy Sees Bill As “Down Payment”
Senate Medicare Vote Suggests $400 Bil. Rx Benefit Is Winning Formula
Senate Medicare Vote Suggests $400 Bil. Rx Benefit Is Winning Formula
PhRMA Agenda Includes Tort Reform; Common Ground With HMOs?
DTC Restrictions Under Consideration For House Medicare Rx Bill
House Democrats Testing Medicare Rx Prices As Campaign Issue
Advertisement
UsernamePublicRestriction

Register

PS041971

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel